Latest news with #ResearchTrianglePark
Yahoo
a day ago
- Business
- Yahoo
JAGGAER Becomes First Source-to-Pay Company to Achieve Elite ISO/IEC 42001 Certification for Artificial Intelligence Management System
Putting responsible and ethical AI at the heart of procurement innovation RESEARCH TRIANGLE PARK, N.C., June 19, 2025--(BUSINESS WIRE)--JAGGAER, a global leader in Source-to-Pay and supplier collaboration, today announced it has achieved ISO/IEC 42001:2023 certification for its Artificial Intelligence Management System (AIMS). This landmark achievement positions JAGGAER as the first company in the Source-to-Pay (S2P) industry to attain this rigorous international standard, underscoring its commitment to the responsible and ethical development and secure deployment of AI technologies. ISO/IEC 42001 is the world's first AI management system standard, designed to help organizations establish, implement, maintain, and continually improve an AIMS. The standard provides a framework for managing the unique challenges posed by AI systems, focusing on trustworthiness, transparency, accountability, and the mitigation of AI-related risks. "This certification is more than a compliance milestone—it reflects our belief that AI must be built on trust, transparency, and accountability," said Gopinath Polavarapu, Chief Digital and AI Officer at JAGGAER. "We're proud to lead the S2P industry in setting a new bar for responsible AI that helps our customers make smarter, safer decisions." The ISO/IEC 42001 certification validates JAGGAER's systematic approach to managing AI, ensuring that all AI-driven features within the JAGGAER One platform are developed and operated with considerations for ethical implications, data governance, security, and continuous improvement. As AI transforms the procurement landscape, this proactive stance on AI governance is not only critical but also confirms the company's longstanding track record in delivering advanced, trustworthy solutions. "Achieving ISO 42001 certification is about delivering real value and confidence to our customers," said Michael Garvin, Chief Information Security Officer at JAGGAER. "It's our commitment that AI is guided by clear, ethical principles to work effectively and fairly for your business. We proactively manage AI risks like security threats and bias, so you can leverage our innovative tools knowing your data and operations are secure. This certification validates that our solutions are built on a foundation of trust and transparency, giving you dependable, high-performing AI you can count on. I would like to congratulate the GRC team and everyone at JAGGAER who helped in this effort." JAGGAER's AI-powered solutions are designed to help organizations optimize their procurement processes, enhance supplier relationships, and gain actionable insights from their spend data. This certification further solidifies JAGGAER's position as a trusted partner for businesses embarking on their digital transformation journeys. About JAGGAER: JAGGAER is a global leader in enterprise procurement and supplier collaboration, and the catalyst for enhancing human decision-making to accelerate business outcomes. We help organizations to manage and automate complex processes while enabling their highly resilient, accountable, and integrated supplier base. Backed by 30 years of expertise, our proven AI-powered industry-specific solutions, services, and partnerships form JAGGAER One, serving direct and indirect, upstream, and downstream, in settings demanding an intelligent and comprehensive source-to-pay solution. Our 1,200 global employees are obsessed with helping customers create value, transform their businesses, and accelerate their journey to Autonomous Commerce. View source version on Contacts For Jaggaer: Josephine OrnagoEmail: pr@ Cell: +39 3662250305 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
JAGGAER Becomes First Source-to-Pay Company to Achieve Elite ISO/IEC 42001 Certification for Artificial Intelligence Management System
Putting responsible and ethical AI at the heart of procurement innovation RESEARCH TRIANGLE PARK, N.C., June 19, 2025--(BUSINESS WIRE)--JAGGAER, a global leader in Source-to-Pay and supplier collaboration, today announced it has achieved ISO/IEC 42001:2023 certification for its Artificial Intelligence Management System (AIMS). This landmark achievement positions JAGGAER as the first company in the Source-to-Pay (S2P) industry to attain this rigorous international standard, underscoring its commitment to the responsible and ethical development and secure deployment of AI technologies. ISO/IEC 42001 is the world's first AI management system standard, designed to help organizations establish, implement, maintain, and continually improve an AIMS. The standard provides a framework for managing the unique challenges posed by AI systems, focusing on trustworthiness, transparency, accountability, and the mitigation of AI-related risks. "This certification is more than a compliance milestone—it reflects our belief that AI must be built on trust, transparency, and accountability," said Gopinath Polavarapu, Chief Digital and AI Officer at JAGGAER. "We're proud to lead the S2P industry in setting a new bar for responsible AI that helps our customers make smarter, safer decisions." The ISO/IEC 42001 certification validates JAGGAER's systematic approach to managing AI, ensuring that all AI-driven features within the JAGGAER One platform are developed and operated with considerations for ethical implications, data governance, security, and continuous improvement. As AI transforms the procurement landscape, this proactive stance on AI governance is not only critical but also confirms the company's longstanding track record in delivering advanced, trustworthy solutions. "Achieving ISO 42001 certification is about delivering real value and confidence to our customers," said Michael Garvin, Chief Information Security Officer at JAGGAER. "It's our commitment that AI is guided by clear, ethical principles to work effectively and fairly for your business. We proactively manage AI risks like security threats and bias, so you can leverage our innovative tools knowing your data and operations are secure. This certification validates that our solutions are built on a foundation of trust and transparency, giving you dependable, high-performing AI you can count on. I would like to congratulate the GRC team and everyone at JAGGAER who helped in this effort." JAGGAER's AI-powered solutions are designed to help organizations optimize their procurement processes, enhance supplier relationships, and gain actionable insights from their spend data. This certification further solidifies JAGGAER's position as a trusted partner for businesses embarking on their digital transformation journeys. About JAGGAER: JAGGAER is a global leader in enterprise procurement and supplier collaboration, and the catalyst for enhancing human decision-making to accelerate business outcomes. We help organizations to manage and automate complex processes while enabling their highly resilient, accountable, and integrated supplier base. Backed by 30 years of expertise, our proven AI-powered industry-specific solutions, services, and partnerships form JAGGAER One, serving direct and indirect, upstream, and downstream, in settings demanding an intelligent and comprehensive source-to-pay solution. Our 1,200 global employees are obsessed with helping customers create value, transform their businesses, and accelerate their journey to Autonomous Commerce. View source version on Contacts For Jaggaer: Josephine OrnagoEmail: pr@ Cell: +39 3662250305
Yahoo
4 days ago
- Business
- Yahoo
IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'
RESEARCH TRIANGLE PARK, N.C., June 16, 2025--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program. IQVIA's breakthrough Health Research Space platform allows direct-to-patient data collection and engagement with patient-facing mobile apps that helps patients and their caregivers participate in decentralized clinical trials around the world. The platform is configurable, multilingual and compatible with web, iOS and Android and is available across many geographic regions, increasing patient access to participate in clinical research. The app improves trial participant engagement and retention and includes robust privacy and security features. By facilitating direct-to-patient data collection, the platform helps to generate real-world evidence for new medicines and innovative medical devices and diagnostics. "IQVIA's mobile app is essential for improving engagement and reaching patients and caregivers. It lets them connect from any location, essentially meeting them where they are, with strong patient privacy safeguards," said Rob Kotchie, president of Real World Solutions at IQVIA. "Our platform meets the needs of real-world decentralized and hybrid studies throughout the drug and device development life cycle, helps to reduce patient burden and enables long-term follow-up. It ensures that patients can participate in studies more easily and for extended periods." The MedTech Breakthrough Awards, a program of Tech Breakthrough, an independent market intelligence organization, recognizes excellence and innovation in the health and medical technology industry. The program honors the companies, products and solutions driving meaningful progress and improving patient care. This year's program received 4,500 entries across all awards, showcasing the global impact and momentum of the digital healthcare industry today. "There's a growing expectation for life sciences organizations to focus on patient-centered and long-term outcome data collection," said Steve Johansson, managing director, Tech Breakthrough. "However, traditional clinical study participation is not possible for all patient populations and includes barriers, such as the need to travel to a research site for in-person appointments. IQVIA's innovative patient-facing app helps reduce barriers to patient participation and provides effective, efficient data collection and engagement. Its streamlined processes make it easy for individuals to engage and take a more active role in managing their health. Congratulations to the IQVIA team on recognition of this solution." To learn more about the IQVIA Health Research Space solution, visit our site. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances in an effort to advance their path toward cures. To learn more, visit About the MedTech Breakthrough Awards Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical and health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information, visit Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose. View source version on Contacts Kerri Joseph, IQVIA Investor Relations ( Alissa Maupin, IQVIA Media Relations (
Yahoo
4 days ago
- Health
- Yahoo
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
RESEARCH TRIANGLE PARK, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data on the long-term efficacy and safety of ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients across all age groups. 'These data from both clinical trials and real-world settings continue to strengthen the evidence that ORLADEYO is an effective and well-tolerated long-term prophylactic treatment for HAE. Importantly, patients report not only fewer and less severe attacks, but also meaningful improvements in daily functioning and emotional well-being. This contributes to the growing body of evidence supporting the use of ORLADEYO as a long-term prophylactic option for adolescents and adults living with HAE,' said Helen Thackray, chief research and development officer of BioCryst. The following four studies were presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025. Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results from APeX-P The ongoing open-label APeX-P study is evaluating the pharmacokinetic, safety, and effectiveness of berotralstat in children aged 2 to 11 years with HAE. Patients were enrolled into four weight-based cohorts. Cohort 1 received a 150 mg capsule once daily; cohorts 2-4 received once-daily oral granule doses of 108 mg, 96 mg and 78 mg, respectively. The median age was 8 years (range: 3–11), with disease onset typically between ages 2–6 years. All patients received standard of care (SOC) treatment for 12 weeks prior to the study. Key results Eighty-six percent reduction in attacks requiring professional care: attacks dropped from 22 during the 12-week SOC period to three following 12 weeks of berotralstat treatment Early/rapid and sustained reduction in the rate of HAE attacks requiring on-demand treatment Mean (SEM) adjusted monthly attack rate decreased from 1.28 (0.25) during SOC to 0.38 (0.13) from day one to week four of berotralstat treatment Sustained reduction for up to 48 weeks of follow-up Berotralstat was well tolerated across all cohorts; the most common treatment-emergent adverse events were nasopharyngitis, upper respiratory tract infection, and headache. Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study The Berolife study is an open-label observational study in France which assessed the real-world tolerability and effectiveness of oral once-daily berotralstat (150 mg) in patients with HAE aged >12 years. A total of 82 patients were enrolled, with a mean (SD) age of 40.0 (17.5) years. The mean (SD) baseline attack rate was 1.1 (1.0) attacks per month (median: 0.83), based on the six months prior to enrollment. Key results Significant reduction in monthly HAE attacks was observed at six months (in patients with follow-up data (n=37)) Median monthly attack rate decreased from 1.0 to 0.44 attacks after six months of berotralstat treatment Sustained reductions in attack frequency maintained at 12, 18, and 24 months Berotralstat was well tolerated throughout the study period Adverse events were consistent with previous clinical trial data Impact of Berotralstat on Quality of Life in Patients with Hereditary Angioedema This analysis assessed the impact of berotralstat on patient-reported quality of life (QoL) outcomes compared to placebo, using pooled data from previous Phase 3 APeX-2 and APeX-J clinical trials which showed that once-daily berotralstat 150 mg significantly reduced the frequency of HAE attacks. This QoL assessment was measured using the validated Angioedema Quality of Life Questionnaire (AE-QoL), which evaluates four key domains: functioning, fatigue/mood, fears/shame, and nutrition. Key results Significant improvements in AE-QoL total and domain scores were observed with berotralstat versus placebo at week 24 Benefits sustained through week 96, indicating lasting improvement in daily life At week 24, 60 percent of patients receiving berotralstat achieved the Minimal Clinically Important Difference (MCID) in AE-QoL total score, compared to 52.4 percent in the placebo group Over time, the proportion of patients reaching MCID increased in the berotralstat cohort, suggesting progressive and cumulative improvements in QoL alongside reductions in HAE attack frequency Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group This qualitative study explored patient experiences with HAE, including their care journey and perceptions of treatment with berotralstat. Focus groups were conducted to gain insight into the real-world impact of berotralstat on patients' daily lives. Seven patients from France, aged 20-70 years, participated in the focus groups. All had been treated with berotralstat for at least six months, with a median age at HAE diagnosis of 28 years. Prior to starting berotralstat, the majority of participants (71 percent) had switched from previous treatments due to long-term tolerability concerns and guidance from health authorities. Key findings Participants reported notable improvements in disease control, including reduced frequency and severity of HAE attacks Minimal side effects were observed Berotralstat was described as less burdensome and easier to incorporate into daily routines compared to previous therapies Improved disease management was associated with reduced psychological distress and a greater sense of normalcy, contributing to enhanced quality of life About ORLADEYO® (berotralstat)ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. U.S. Indication and Important Safety Information INDICATIONORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. Limitations of useThe safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation. IMPORTANT SAFETY INFORMATIONAn increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent. The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease. A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C). Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein. P-gp inducers (eg, rifampin, St. John's wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO. ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO. The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established. There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production. To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or Please see full Prescribing Information. About BioCryst PharmaceuticalsBioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements, including statements relating to ORLADEYO safety, performance and effectiveness. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; interim results of a clinical trial do not necessarily predict final results; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay, or withdraw market approval for products and product candidates; and BioCryst's ability to successfully manage its growth and compete effectively. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's forward-looking statements. BCRXW Contact:John Bluth+1 919 859 7910jbluth@ Niamh Lyons+353 87 7745000nlyons@
Associated Press
28-05-2025
- Business
- Associated Press
Toshiba Hardware and Software Leaders Win National Women of Influence Award for Transformative Contributions to Retail Technology
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 28, 2025-- Honoring their innovations and impact on the retail technology industry, Stacy Arrington and Johanna Hinkle from Toshiba Global Commerce Solutions have been named 2025 recipients of The Shelby-Griffin Report's Women of Influence in the Food Industry Award. This prestigious recognition celebrates two standout leaders whose work embodies Toshiba's commitment to driving innovation, operational excellence, and customer success in the evolving food retail industry. This press release features multimedia. View the full release here: 'At Toshiba, our strength as a global leader in retail technology is built on a foundation of innovation, deep expertise, and an unwavering commitment to our customers,' said Rance Poehler, President and CEO of Toshiba Global Commerce Solutions. 'Leaders like Stacy and Johanna bring that foundation to life every day. Their vision, creativity, and impact reflect the very best of who we are as a company and how we help propel the industry forward.' As Manager of Hardware Development, Arrington is instrumental in bringing next-generation retail solutions to life, including the new MxP™ Vision Kiosk, an advanced product recognition system designed specifically for high-volume, small-format food retailers. Backed by over 20 years in the industry and recognized as a Toshiba Master Inventor with 20 patents, she blends deep technical expertise with a strong understanding of real-world customer needs. 'I'm proud to be part of a company that not only invests in groundbreaking technology but also in the people who bring those ideas to life,' said Arrington. 'As we build the future of food retail, I hope my journey encourages more women to pursue their passions, lead boldly, and know they belong in every room where innovation happens.' In 2024, Arrington took on a formal leadership role where she now influences product strategy and mentors Toshiba's next generation of engineers and interns. Her ability to lead with empathy, precision, and a relentless focus on customer success underscores her value to the broader retail technology ecosystem. Hinkle is a driving force behind Toshiba's retail innovation strategy, playing a critical role in developing and expanding the ELERA® Security Suite. In her role as Director of AI & Automation Solutions, Hinkle empowers food retailers to tackle shrink, one of the industry's most pressing challenges. Under her leadership, ELERA Security Suite has evolved into a global solution delivering measurable return on investment and operational resilience for retailers. 'Innovation isn't just about building technology—it's about challenging assumptions, empowering others, and solving the problems that matter most. I'm proud to be part of a company that empowers women, champions bold thinking, and is transforming how retailers fight shrink and drive smarter business outcomes. Together, we're redefining the industry's future,' said Hinkle. Known for her ability to translate complex challenges into scalable, effective solutions, Hinkle also serves as a mentor and innovation champion within Toshiba. Her commitment to supporting women in technology and nurturing future innovators exemplifies the company's values of empowerment and leadership. The Shelby Report selects Women of Influence winners for demonstrating a superior level of dedication and professionalism in the success of their company and the industry, as well as leadership through other initiatives such as charity, philanthropy, or civic work. About Toshiba Global Commerce Solutions: Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers' ever-changing needs. Visit and engage with us on: LinkedIn - YouTube - Facebook - Instagram: @toshibacommerce X/Twitter: @ToshibaCommerce Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange. View source version on CONTACT: MEDIA CONTACT: Toshiba Global Commerce Solutions Elizabeth Romero / Amy Gray [email protected] [email protected] KEYWORD: NORTH CAROLINA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HARDWARE RETAIL SECURITY DATA MANAGEMENT TECHNOLOGY FOOD TECH SUPPLY CHAIN MANAGEMENT ONLINE RETAIL OTHER RETAIL ARTIFICIAL INTELLIGENCE RESTAURANT/BAR OTHER TECHNOLOGY SOFTWARE NETWORKS FOOD/BEVERAGE SOURCE: Toshiba Copyright Business Wire 2025. PUB: 05/28/2025 08:25 AM/DISC: 05/28/2025 08:24 AM
